Kytopen Partners with T-CURX to Advance CAR-T Cell Therapy Manufacturing in Europe
In a significant move that heralds new opportunities in CAR-T cell therapies, Kytopen Corp., a pioneer in non-viral cellular engineering, has announced a partnership with T-CURX GmbH, a biopharmaceutical company based in Würzburg, Germany. This collaboration is marked by an agreement that grants T-CURX access to Kytopen's cutting-edge Flowfect Tx™ cellular engineering platform through its Technology Access Program (TAP). This agreement not only underscores the expansion of Kytopen's reach into Europe but also represents a strategic commitment to enhance the development of advanced cell therapies aimed at treating cancer.
Kytopen specializes in non-viral, continuous flow technology that has proven effective in producing engineered cells quickly and efficiently. The Flowfect Tx™ platform is designed to facilitate the scalable production of high-quality engineered cells, essential for developing robust CAR-T therapies. For T-CURX, gaining on-site access to this technology was a pivotal factor in their decision to form this partnership. The Flowfect Tx™ platform's validation for GMP (Good Manufacturing Practice) standards, coupled with its capacity for clinical and commercial-scale manufacturing, aligns perfectly with T-CURX's mission to deliver cutting-edge personalized immunotherapy treatments.
The collaboration is set to leverage Kytopen's Flowfect technology, which optimizes gene delivery processes by allowing the controlled flow-based processing of cellular materials. This enables the production of hundreds of billions of engineered cells in just a matter of minutes, thereby significantly lowering the barrier to scale-up for cell therapies. T-CURX will benefit from the extensive proof of concept process developments offered under this partnership—all supported by Kytopen’s specialized Field Applications Team.
Kytopen's CEO, Michael Chiu, expressed enthusiasm about working with T-CURX, emphasizing the vast potential of the European market for advanced cell therapies. This venture is geared towards accelerating the delivery of innovative treatments for patients battling cancer, autoimmune diseases, and other serious health conditions. T-CURX's CEO, Ulf Grawunder, echoed this sentiment, noting that the ability to produce CAR-T therapies within a GMP framework aligns with their goal of democratizing access to these advanced treatments. The collaboration is anticipated to not only accelerate the clinical availability of CAR-T therapies but also to make them more scalable and affordable, addressing a high medical need in the field.
Kytopen's reputation in the industry is built on its ability to deliver engineered cells efficiently and effectively. Their Flowfect® technology is already making waves in the biotechnology sector, and this partnership with T-CURX stands to broaden its impact substantially across Europe. Both companies are committed to pushing the boundaries of what's possible in cell therapy manufacturing, ultimately leading to more effective treatment options for patients everywhere.
This collaboration marks the beginning of a promising chapter in the realm of CAR-T therapies, where innovation meets necessity in a fight against cancer. As Kytopen and T-CURX embark on this journey together, they are poised to set a new standard in the production of life-saving therapies, making strides toward a future where advanced, patient-centric treatments are accessible to all who need them.
Kytopen specializes in non-viral, continuous flow technology that has proven effective in producing engineered cells quickly and efficiently. The Flowfect Tx™ platform is designed to facilitate the scalable production of high-quality engineered cells, essential for developing robust CAR-T therapies. For T-CURX, gaining on-site access to this technology was a pivotal factor in their decision to form this partnership. The Flowfect Tx™ platform's validation for GMP (Good Manufacturing Practice) standards, coupled with its capacity for clinical and commercial-scale manufacturing, aligns perfectly with T-CURX's mission to deliver cutting-edge personalized immunotherapy treatments.
The collaboration is set to leverage Kytopen's Flowfect technology, which optimizes gene delivery processes by allowing the controlled flow-based processing of cellular materials. This enables the production of hundreds of billions of engineered cells in just a matter of minutes, thereby significantly lowering the barrier to scale-up for cell therapies. T-CURX will benefit from the extensive proof of concept process developments offered under this partnership—all supported by Kytopen’s specialized Field Applications Team.
Kytopen's CEO, Michael Chiu, expressed enthusiasm about working with T-CURX, emphasizing the vast potential of the European market for advanced cell therapies. This venture is geared towards accelerating the delivery of innovative treatments for patients battling cancer, autoimmune diseases, and other serious health conditions. T-CURX's CEO, Ulf Grawunder, echoed this sentiment, noting that the ability to produce CAR-T therapies within a GMP framework aligns with their goal of democratizing access to these advanced treatments. The collaboration is anticipated to not only accelerate the clinical availability of CAR-T therapies but also to make them more scalable and affordable, addressing a high medical need in the field.
Kytopen's reputation in the industry is built on its ability to deliver engineered cells efficiently and effectively. Their Flowfect® technology is already making waves in the biotechnology sector, and this partnership with T-CURX stands to broaden its impact substantially across Europe. Both companies are committed to pushing the boundaries of what's possible in cell therapy manufacturing, ultimately leading to more effective treatment options for patients everywhere.
This collaboration marks the beginning of a promising chapter in the realm of CAR-T therapies, where innovation meets necessity in a fight against cancer. As Kytopen and T-CURX embark on this journey together, they are poised to set a new standard in the production of life-saving therapies, making strides toward a future where advanced, patient-centric treatments are accessible to all who need them.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.